SGLT2 Inhibitors and Electrolyte Management in Diabetes, Heart Failure, and Kidney Disease
This community focuses on the clinical application of sodium-glucose cotransporter-2 inhibitors and the management of sodium and potassium balance in patients with type 2 diabetes, heart failure, and chronic kidney disease.
The research centers on the pharmacological effects of SGLT2 inhibitors on glucose regulation, blood pressure, and renal function. A significant portion of the work examines the interplay between dietary sodium intake, serum potassium levels, and cardiovascular outcomes. Studies frequently address the risk of diabetic ketoacidosis and the management of ejection fraction in heart failure patients. The literature also includes substantial analysis of lithium therapy in bipolar disorder, reflecting the community's broad focus on electrolyte-sensitive conditions. Methodologies range from randomized controlled trials and systematic meta-analyses to case reports and large-scale prevalence studies, all aimed at optimizing treatment protocols for these interconnected metabolic and cardiovascular disorders.
This community represents 5.7% of all sodium research and 5.7% of all potassium research, with 18,441 and 11,843 papers respectively. It also accounts for 2.9% of lithium research, comprising 7,406 papers.
The community comprises 47,593 papers, published primarily in the Journal of Biological Chemistry, The Lancet, and Hypertension.
Recent work continues to focus on the cardiovascular and renal benefits of SGLT2 inhibitors, including perioperative management and combination therapies for chronic kidney disease. Newer studies also address the metabolic effects of GLP-1 agonists and the mechanisms of diabetic kidney disease.